Ensuring Patient Safety in Clinical Trials FP7 Project: Linked2Safety Dr. Ratnesh Sahay, Dr. Ronan Fox DERI, NUIG Galway, Ierland Convergence Meeting:

Slides:



Advertisements
Similar presentations
S.O.S. eHealth Project Open eHealth initiative for a European large scale pilot of patient summary and electronic prescription Daniel Forslund, Head of.
Advertisements

Areas of Research Specific issues. Clinical Trials Phase I First use in humans of an experimental drug or treatment In a small group of healthy volunteers.
1 Large research and medical databases in clinical and research multi-centres trials A Swiss Perspective June 19, 2012 European Commission International.
NIGB Legal requirements for use of personal data in research OnCore UK / NRES Training workshop Ethical Principles relating to consent for use of samples.
EHR stakeholder workshop – 11th October EHR integration for clinical research: toward new interaction models ? Isabelle de Zegher.
Safety Reporting IN Clinical Trials
Primary and secondary use of EHR: Enhancing clinical research Pharmaceutical Industry Perspectives Dr. Karin Heidenreich Senior Public Affairs Manager/Novartis.
Linked2Safety Project (FP7-ICT – 5.3) A NEXT-GENERATION, SECURE LINKED DATA MEDICAL INFORMATION SPACE FOR SEMANTICALLY-INTERCONNECTING ELECTRONIC.
 Copyright 2011 Digital Enterprise Research Institute. All rights reserved. Digital Enterprise Research Institute Enabling Networked Knowledge.
 Copyright 2005 Digital Enterprise Research Institute. All rights reserved. SAOR: Semantically Annotated Oncology and Radiology Progress.
Legal Aspect of IPv6 and of the IPv4 to IPv6 transition Ashok.B.RADHAKISSOON Legal Adviser/Policy&Regulatory Affairs Liaison.
) Linked2Safety Project (FP7-ICT – 5.3 ) A NEXT-GENERATION, SECURE LINKED DATA MEDICAL INFORMATION SPACE FOR SEMANTICALLY-INTERCONNECTING ELECTRONIC.
) Linked2Safety Project (FP7-ICT – 5.3 ) A NEXT-GENERATION, SECURE LINKED DATA MEDICAL INFORMATION SPACE FOR SEMANTICALLY-INTERCONNECTING ELECTRONIC.
© Safeguarding public health BIOABSORBABLE STENTS: REGULATORY ISSUES DR SUSANNE LUDGATE Clinical Director Medicines and Healthcare products Regulatory.
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
2/16/2010 The Family Educational Records and Privacy Act.
Clinical Trials Scientific Aspects AND Legal & Procedural Aspects M K Unnikrishnan [Aug 2006]
Trial Procedures and Forms
Linked2Safety Project (FP7-ICT – 5.3) A NEXT-GENERATION, SECURE LINKED DATA MEDICAL INFORMATION SPACE FOR SEMANTICALLY-INTERCONNECTING ELECTRONIC.
EMERGING AND RE-EMERGING INFECTIOUS DISEASES: A CONTINUOUS CHALLENGE FOR EUROPE STOA - AVIESAN Workshop June 19th 2012, European Parliament, Bruxelles.
DATA PROTECTION AND PATIENT CONFIDENTIALITY IN RESEARCH Nic Drew Data Protection Manager University Hospital of Wales   
Healing Hands Clinical Research Services is a Site Management organization with broad spectrum of activities.
EGovernment Interoperability: Concepts, research results from the IST EU-Publi.com project and plans for a European study at local and regional level within.
Medical Research BADRAG meeting Jan 2013 Dr H Sari-Kouzel.
) Linked2Safety Project (FP7-ICT – 5.3 ) A NEXT-GENERATION, SECURE LINKED DATA MEDICAL INFORMATION SPACE FOR SEMANTICALLY-INTERCONNECTING ELECTRONIC.
1 IQCS AGM November 2009 IQCS Data Protection Workshop Scenarios / Answers 12 th November 2009.
) Linked2Safety Project (FP7-ICT – 5.3 ) A NEXT-GENERATION, SECURE LINKED DATA MEDICAL INFORMATION SPACE FOR SEMANTICALLY-INTERCONNECTING ELECTRONIC.
Requirements of EU pharmacovigilance legislation for distributors Julia Sipos Quality Management Director Pharmacovigilance coordinator Version 03.
Translational Research and Patient Safety in Europe TRANSFoRm: Requirements analysis for the learning healthcare system.
05/09/2015www.ecrin.org1 European Clinical Research Infrastructures Network
Institutional Visits III KAM, Bratislava 4th to 8th September 2013.
) Linked2Safety Project (FP7-ICT – 5.3 ) A NEXT-GENERATION, SECURE LINKED DATA MEDICAL INFORMATION SPACE FOR SEMANTICALLY-INTERCONNECTING ELECTRONIC.
EHR Clinical data repository and pharmacovigilance Suzanne Markel-Fox 12 October 2007.
Integrated Biomedical Information for Better Health Workprogramme Call 4 IST Conference- Networking Session.
METU-SRDCEUROREC Meeting, Geneva, October 10, 2006 RIDE Overview Asuman Dogac Middle East Technical University Ankara, Turkey.
Legal & Ethical Issues. Objectives At the completion of this session the participant will be able to: ◦ Describe the ethical principles associated with.
Linked2Safety Project (FP7-ICT – 5.3) A NEXT-GENERATION, SECURE LINKED DATA MEDICAL INFORMATION SPACE FOR SEMANTICALLY-INTERCONNECTING ELECTRONIC.
CLINICAL TRIALS IN NEW DRUG DEVELOPMENT Michael A Ross,M.D. President CPL Inc.
) Linked2Safety Project (FP7-ICT – 5.3 ) A NEXT-GENERATION, SECURE LINKED DATA MEDICAL INFORMATION SPACE FOR SEMANTICALLY-INTERCONNECTING ELECTRONIC.
Process of FDA New Drug Approval: 1- New Compound with promising preclinical data 2- Sponsor applies to FDA for an IND (Investigational New Drug Application)
Topic 3A SEMANTIC INTEROPERABILITY: REUSE OF EHR DATA Mats Sundgren.
© Enterprise Europe Network South West 2009 The Eurostars Programme Kenny Legg R&D Funding for the Environmental Sector – 29 June 2010 European Commission.
Access to drugs, Reducing bottlenecks Matt Cooper Business Development & Marketing Director NIHR Clinical Research Network
Risk Management Standards and Guidelines
Expanding Access to Canadian Derivatives Clearing.
Pharmacovigilance Convention Centre, Symbiosis Lavale Campus, Pune.
CLINICAL TRIALS – PHASE IV. PHASE IV  Phase IV are post marketing studies and provide basis for continued marketing. They may also provide information.
Using Australian Clinical Sites – Challenges for International Sponsors Prof A J (Tony) Webber Clinical Network Services Pty Ltd Brisbane, Australia.
TRANSFoRm A flexible zone model for data privacy and confidentiality in medical research Wolfgang Kuchinke 1,Christian Ohmann, 1 Evert-Ben van Veen 2,
European University Presses: Some Perspectives from the Mainland 1.
httpwww.youtube.com/watch?v=DhxD6sVQEYc:// The Drug Discovery Process.
The process of drug development. Drug development 0,8 – 1 mld. USD.
Collaborative Institutional Training Initiative (CITI) citiprogram.org Georgia Institute of Technology.
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024 Pharmacovigilance Market Size,
Biopharma Breakout Goals
Drug Discovery &Development
MAINTAINING THE INVESTIGATOR’S SITE FILE
The European Union (EU) policy challenge
NAP6 Perioperative Anaphylaxis
Schedule 2 Drugs Henderson.
Vikas Dhikav, PhD Clinical Trials Vikas Dhikav, PhD
© 2010 Jones and Bartlett Publishers, LLC
© 2010 Jones and Bartlett Publishers, LLC
Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.
MAINTAINING THE INVESTIGATOR’S STUDY FILE
Pharmaceuticals Industry
TRACE INITIATIVE: Confidentiality, Data Security, and Procedures for Protocol Violation or Adverse Event.
Design Issues in Human studies of Psychopharmacology placebo controls double blind studies.
eHR Clinical data repository and pharmacovigilance
Presentation transcript:

Ensuring Patient Safety in Clinical Trials FP7 Project: Linked2Safety Dr. Ratnesh Sahay, Dr. Ronan Fox DERI, NUIG Galway, Ierland Convergence Meeting: Semantic Interoperability for Clinical Research & Patient Safety in Europe 1/15

Partners Convergence Meeting: Semantic Interoperability for Clinical Research & Patient Safety in Europe 1.INTRASOFT INTERNATIONAL SA, Belgium 2.UNIVERSITY OF CYPRUS, Cyprus 3.DERI-NATIONAL UNIVERSITY OF IRELAND, GALWAY, Ireland 4.UNIVERSITY OF MANCHESTER, UK 5.CENTRE FOR RESEARCH AND TECHNOLOGY HELLAS (CERTH), Greece 6.SIVECO Romania S.A 7.UBITECH Research, Greece 8.GOTTFRIED WILHELM LEIBNIZ UNIVERSITAET HANNOVER (LUH), Germany 9.Cyprus Institute of Neurology and Genetics (CING), Greece 10.ZEINCRO Hellas S.A., Greece 11. HOSPICES CANTONAUX CHUV, Switzerland 2/15

The Problem return number of subjects (i.e., patients) that have been administered the drug Insulin and exhibit BMI > 25 and Dyslipidemia and Agoraphobia as adverse events RxNormLOINCSNOMED DSM-4 Legal and Ethical Regulations HL7/openEHR 3/15 Convergence Meeting: Semantic Interoperability for Clinical Research & Patient Safety in Europe

Showcases Convergence Meeting: Semantic Interoperability for Clinical Research & Patient Safety in Europe  Phase III Clinical Trial – Subject Selection Criteria  the unbiased randomised selection of subjects in phase III clinical trials  e.g. return subjects with diabetesValue > 4 and weight >80 and hasCancer  Phase IV – Post Marketing Surveillance  the pharmacovigilance of a drug after it receives permission to be sold  e.g. Test DrugX association with headaches  Phase IV – Chemoinformatics  identification of relations between molecular fragments and specific adverse drug event categories  e.g. Test chemicalFragmentX (of DrugX) with rash 4/15

Objectives  Enable Patient Safety in clinical trials  anonymisation of clinical site  anonymisation of clinical data  Build a semantically-interlinked medical information space  recruit patients across European clinical data sets  adverse event detection  Support effective organization and execution of clinical trials  embedding governance / legal / ethics in process Convergence Meeting: Semantic Interoperability for Clinical Research & Patient Safety in Europe 5/15

Safety First – Ethical & Legal Aspects Convergence Meeting: Semantic Interoperability for Clinical Research & Patient Safety in Europe  Respect patients’ anonymity, data’s ownership and privacy  Not possible to transfer or copy patient data from the originating institutions  All machines that hold patient data are need to remain off- line  Clinical data will not be identifiable and should not lead to the identification of a person’s identity (either directly or indirectly e.g. back-tracing)  Strictly adhere to consent form requirements and all ethical and legal issues (European and national) 6/15

Data Anonymisation  Addresses legal and ethical issues by  Closed-world room pre-processing  Usage of data-cubes Convergence Meeting: Semantic Interoperability for Clinical Research & Patient Safety in Europe 7/15

Is data anonymised enough ? 16 year old widow Problem Marital Status Age MarriedWidowedSingle ~ /15 Convergence Meeting: Semantic Interoperability for Clinical Research & Patient Safety in Europe

16 year old widow Problem Marital Status Age MarriedWidowedSingle ~ Is data anonymised enough ? 9/15 Convergence Meeting: Semantic Interoperability for Clinical Research & Patient Safety in Europe

Perturbation and Cell Suppression Original Data Marital Status Age Married Widowe dSingle ~ Marital Status Age Married Widowe dSingle 0-16NA ~ Perturbation (+-1) and Cell Suppression (<5) 10/15 Convergence Meeting: Semantic Interoperability for Clinical Research & Patient Safety in Europe

Linked2Safety – Approach Linked Data Cubes Semantic EHR ModelPolicy Model 11/15 Convergence Meeting: Semantic Interoperability for Clinical Research & Patient Safety in Europe

Semantic EHR Model ACGT BFO imports Domain SEHR CHUV Cardiovascular Psychiatric Adverse Events CING Breast Cancer Diabetic Neurology Genetics Adverse Event (AE) ZEINCRO Adverse Event (AE) Concomitant Medication (CE) Respiratory UPPER UMLS, OBO Foundry (Basic Formal Ontology) Advancing Clinico-Genomic Trials on Cancer (ACGT) Class1859 Object Property225 Data Property575 12/15 Convergence Meeting: Semantic Interoperability for Clinical Research & Patient Safety in Europe

Policy-Based User Restricted Resources R1R3 P1 R4 P3 R2 P2 R5 P4 Data Cube + R1# P4 Query R1R5 P4 Result R1R3 R5 P4 View P1 R1 # P1 # # P4 Access Policy   13/15 Convergence Meeting: Semantic Interoperability for Clinical Research & Patient Safety in Europe

Current Status  Basic prototypes completed  Data-cube building at clinical sites  Special Interest Group (SIG) recruitment  Legal ethical framework and exploitation strategy 14/15 Convergence Meeting: Semantic Interoperability for Clinical Research & Patient Safety in Europe

Contact Dr. Ratnesh Sahay, Dr. Ronan Fox DERI, NUIG Tel: Fax: Join Thank You 15/15 Convergence Meeting: Semantic Interoperability for Clinical Research & Patient Safety in Europe